These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19878656)

  • 1. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease.
    Qing H; Zhang Y; Deng Y; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1229-34. PubMed ID: 19878656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 variation and dementia with Lewy bodies.
    Heckman MG; Soto-Ortolaza AI; Contreras MYS; Murray ME; Pedraza O; Diehl NN; Walton R; Labbé C; Lorenzo-Betancor O; Uitti RJ; van Gerpen J; Ertekin-Taner N; Smith GE; Kantarci K; Savica R; Jones DT; Graff-Radford J; Knopman DS; Lowe VJ; Jack CR; Petersen RC; Parisi JE; Rademakers R; Wszolek ZK; Graff-Radford NR; Ferman TJ; Dickson DW; Boeve BF; Ross OA
    Parkinsonism Relat Disord; 2016 Oct; 31():98-103. PubMed ID: 27521182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions.
    Waxman EA; Covy JP; Bukh I; Li X; Dawson TM; Giasson BI
    J Neuropathol Exp Neurol; 2009 Jul; 68(7):785-96. PubMed ID: 19535993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
    Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
    J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
    Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
    Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
    Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
    Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
    Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
    Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
    Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
    Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
    Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.
    Carballo-Carbajal I; Weber-Endress S; Rovelli G; Chan D; Wolozin B; Klein CL; Patenge N; Gasser T; Kahle PJ
    Cell Signal; 2010 May; 22(5):821-7. PubMed ID: 20074637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
    Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
    Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
    Gomez A; Ferrer I
    Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.